Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LivaNova PLC stock logo
LIVN
LivaNova
$55.90
+5.8%
$46.42
$32.48
$57.35
$3.05B0.92806,134 shs728,016 shs
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$7.31
+4.0%
$6.65
$5.47
$10.14
$1.08B1.79802,109 shs1.08 million shs
Envista Holdings Corporation stock logo
NVST
Envista
$21.67
+5.9%
$20.04
$14.22
$23.00
$3.61B12.65 million shs1.56 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$68.57
-1.8%
$81.95
$41.50
$90.32
$3.64B-2.561.65 million shs1.15 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LivaNova PLC stock logo
LIVN
LivaNova
+5.75%+4.06%+26.70%+33.48%+20.73%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
+3.98%+2.81%+5.48%+10.26%+11.26%
Envista Holdings Corporation stock logo
NVST
Envista
+6.04%+4.88%+4.35%+29.49%+20.32%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-1.76%-4.27%-21.59%-10.82%+32.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LivaNova PLC stock logo
LIVN
LivaNova
1.713 of 5 stars
1.53.00.00.03.61.71.3
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
3.243 of 5 stars
3.54.00.00.03.21.70.6
Envista Holdings Corporation stock logo
NVST
Envista
3.8405 of 5 stars
2.23.00.03.83.50.01.9
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.5685 of 5 stars
4.51.00.04.62.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LivaNova PLC stock logo
LIVN
LivaNova
3.00
Buy$59.716.82% Upside
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
3.00
Buy$12.0064.16% Upside
Envista Holdings Corporation stock logo
NVST
Envista
2.33
Hold$20.92-3.44% Downside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.08
Buy$115.0967.84% Upside

Current Analyst Ratings Breakdown

Latest MDXG, SLNO, NVST, and LIVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2025
LivaNova PLC stock logo
LIVN
LivaNova
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$55.00 ➝ $58.00
8/20/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$123.00
8/18/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00 ➝ $110.00
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$97.00 ➝ $106.00
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$105.00 ➝ $110.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $25.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$15.00 ➝ $18.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $19.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $17.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$17.00 ➝ $19.00
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LivaNova PLC stock logo
LIVN
LivaNova
$1.25B2.44$4.24 per share13.18$20.56 per share2.72
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$348.88M3.10$0.33 per share22.06$1.46 per share5.01
Envista Holdings Corporation stock logo
NVST
Envista
$2.51B1.43$1.66 per share13.07$18.89 per share1.15
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$4.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LivaNova PLC stock logo
LIVN
LivaNova
$63.23M-$3.8917.4717.80N/A-16.13%14.57%6.91%10/29/2025 (Estimated)
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$42.42M$0.2124.3722.84N/A8.84%23.03%17.09%10/29/2025 (Estimated)
Envista Holdings Corporation stock logo
NVST
Envista
-$1.12B$0.3225.2617.911.162.11%4.84%2.68%10/29/2025 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$175.85M-$4.140.00N/AN/AN/A-73.74%-56.67%11/5/2025 (Estimated)

Latest MDXG, SLNO, NVST, and LIVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
LivaNova PLC stock logo
LIVN
LivaNova
$0.84$1.05+$0.21$0.50$332.20 million$352.50 million
8/6/2025Q2 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 million
7/31/2025Q2 2025
Envista Holdings Corporation stock logo
NVST
Envista
$0.24$0.26+$0.02$0.16$638.21 million$682.10 million
7/30/2025Q2 2025
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$0.06$0.10+$0.04$0.06$90.79 million$98.61 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LivaNova PLC stock logo
LIVN
LivaNova
N/AN/AN/AN/AN/A
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
N/AN/AN/AN/AN/A
Envista Holdings Corporation stock logo
NVST
Envista
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LivaNova PLC stock logo
LIVN
LivaNova
0.31
1.29
1.09
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
0.08
4.39
3.90
Envista Holdings Corporation stock logo
NVST
Envista
0.46
2.44
2.08
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.21
15.13
15.01

Institutional Ownership

CompanyInstitutional Ownership
LivaNova PLC stock logo
LIVN
LivaNova
97.64%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
79.15%
Envista Holdings Corporation stock logo
NVST
Envista
N/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%

Insider Ownership

CompanyInsider Ownership
LivaNova PLC stock logo
LIVN
LivaNova
0.29%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
1.70%
Envista Holdings Corporation stock logo
NVST
Envista
0.66%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
LivaNova PLC stock logo
LIVN
LivaNova
2,90054.60 million54.44 millionOptionable
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
870147.96 million145.44 millionOptionable
Envista Holdings Corporation stock logo
NVST
Envista
12,300166.18 million165.09 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3053.15 million49.74 millionOptionable

Recent News About These Companies

Research Analysts Set Expectations for SLNO Q3 Earnings
Q3 EPS Forecast for Soleno Therapeutics Boosted by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

LivaNova stock logo

LivaNova NASDAQ:LIVN

$55.90 +3.04 (+5.75%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$55.90 0.00 (0.00%)
As of 08/22/2025 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

MiMedx Group stock logo

MiMedx Group NASDAQ:MDXG

$7.31 +0.28 (+3.98%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$7.30 0.00 (-0.07%)
As of 08/22/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Envista stock logo

Envista NYSE:NVST

$21.67 +1.21 (+5.91%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$21.72 +0.05 (+0.24%)
As of 08/22/2025 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$68.57 -1.23 (-1.76%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$68.60 +0.03 (+0.04%)
As of 08/22/2025 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.